ライフサイエンスコーパス: valaciclovir

1 alaciclovir 1 g three times daily (high-dose valaciclovir).

2 First-line treatment for chronic EM is valaciclovir.

3 clovir), and standard-dose valaciclovir with valaciclovir 1 g three times daily (high-dose valaciclov

4 tandard-dose valaciclovir than for high-dose valaciclovir (10 h vs 7 h; p=0.03), but did not differ s

5 aciclovir (20.2; p=0.54), and standard-dose valaciclovir (14.9) versus high-dose valaciclovir (16.5;

6 rd-dose valaciclovir (14.9) versus high-dose valaciclovir (16.5; p=0.34), but did for no medication (

7 ciated with less shedding than standard-dose valaciclovir (198 [4.2%] vs 209 [4.5%]; IRR 0.79, 95% CI

8 tandard-dose valaciclovir than for high-dose valaciclovir (2.5 vs 3.0; p=0.001), but no significant d

9 d not differ significantly for standard-dose valaciclovir (22.6) versus high-dose aciclovir (20.2; p=

10 Patients were randomized to receive valaciclovir (250 mg, 500 mg, or 1 g once daily, or 250

11 00 mg twice daily (standard-dose aciclovir), valaciclovir 500 mg daily (standard-dose valaciclovir) w

12 ing regimen received prophylaxis with either valaciclovir 500 mg orally daily or valganciclovir 450 m

13 atients were randomised (1:1) by computer to valaciclovir (8 g daily) or no additional treatment for

14 Valaciclovir, 8 g/day, was compared with acyclovir, 3.2

15 Administration of oral valaciclovir, a valine ester of acyclovir, achieves suff

16 Twice-daily valaciclovir and acyclovir were similar in effectiveness

17 t differ significantly between standard-dose valaciclovir and high-dose aciclovir (8 h vs 8 h; p=0.23

18 Seven of 20 patients enrolled on the valaciclovir arm experienced CMV reactivation.

19 All valaciclovir dosages were significantly more effective t

20 The aim of the present study was to evaluate valaciclovir efficacy in this setting using a revised pr

21 A randomized, double-blind study of valaciclovir for suppression of recurrent genital herpes

22 Here, we administered valaciclovir for up to 12 months in mice with establishe

23 valaciclovir group than in the standard-dose valaciclovir group (164 [3.3%] vs 292 [5.8%]; 0.54, 0.44

24 CMV disease was significantly longer for the valaciclovir group (P = .03).

25 Shedding was less frequent in the high-dose valaciclovir group than in the standard-dose valaciclovi

26 All pregnant women treated with valaciclovir in 2020-2022 who met the same criteria as i

27 provides further evidence of the efficacy of valaciclovir in preventing vertical transmission of cyto

28 Thus, valaciclovir is highly effective and well tolerated for

29 higher frequency of headaches with high-dose valaciclovir (n=13, 30%) than with other regimens, all r

30 The greatest effect of valaciclovir on CMV disease was seen in patients who wer

31 rly versus late treatment with acyclovir and valaciclovir on zoster-associated pain was assessed from

32 One gram of valaciclovir once daily, 250 mg of valaciclovir twice da

33 year were effectively managed with 500 mg of valaciclovir once daily.

34 treated volunteers with either valacyclovir (valaciclovir) or no antiviral therapy for 1 year and mea

35 e confirmed CMV disease rate was 11.7% among valaciclovir recipients and 17.5% in the pooled acyclovi

36 A trend toward earlier mortality for valaciclovir recipients was seen (P = .06).

37 rterial stiffness and whether treatment with valaciclovir reduces this cell population.

38 lationship (P < .0001) across the once-daily valaciclovir regimens.

39 tion about CMV disease in AIDS patients, and valaciclovir showed activity as both a preemptive and pr

40 Valaciclovir significantly reduces the risk of CMV disea

41 (13 h vs 7 h; p=0.01) and for standard-dose valaciclovir than for high-dose valaciclovir (10 h vs 7

42 (3.3 vs 2.9; p=0.02), and for standard-dose valaciclovir than for high-dose valaciclovir (2.5 vs 3.0

43 us randomized placebo-controlled study found valaciclovir to be effective in reducing the rate of ver

44 Among 178 women who completed valaciclovir treatment, amniocentesis was positive for c

45 ffness, and its expansion is attenuated with valaciclovir treatment.

46 e gram of valaciclovir once daily, 250 mg of valaciclovir twice daily, or 400 mg of acyclovir twice d

47 In the valaciclovir versus acyclovir study (in patients > or =

48 ering a controlled trial of prophylaxis with valaciclovir versus acyclovir.

49 nt difference was recorded for standard-dose valaciclovir versus high-dose aciclovir (2.7 vs 2.8; p=0

50 Valaciclovir was provided for trial 3 for free by GlaxoS

51 proportion of positive amniocentesis in the valaciclovir was significantly lower than the placebo ar

52 r-associated pain compared with placebo (and valaciclovir was superior to acyclovir in this regard) e

53 Famciclovir and valaciclovir were approved for use in the treatment of h

54 ily (high-dose aciclovir), and standard-dose valaciclovir with valaciclovir 1 g three times daily (hi

55 r), valaciclovir 500 mg daily (standard-dose valaciclovir) with aciclovir 800 mg three times daily (h